Home › Calculator › KYKOF Dividend Calculator 2026
KYKOF Dividend DRIP Calculator 2026
2.91% YieldHealthcareKyowa Kirin Co., Ltd. · OTC
Price: $14.43 · Annual div: $0.42/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When KYKOF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your KYKOF snowball 📈
$10,000 in KYKOF → $1.27M in 10 years · $517.55/month
About Kyowa Kirin Co., Ltd. (KYKOF) — Dividend Analysis 2026
Kyowa Kirin Co., Ltd. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of medicines, with a primary focus on therapeutic areas including oncology, nephrology, central nervous system disorders, and immunological conditions. The company's extensive pharmaceutical portfolio encompasses solutions across its core therapeutic areas. Within oncology, key products include ABSTRAL, a sublingual fentanyl formulation for breakthrough cancer pain management, and LEUNASE, utilized for acute lymphoblastic leukemia. They also offer GRAN, a human colony-stimulating factor, and the G-LASTA/Peglasta/Neulasta range, developed to address chemotherapy-induced febrile neutropenia. Pain management also includes PecFent, a nasal spray, while SANCUSO is available to treat chemotherapy-related nausea and vomiting. POTELIGEO, a humanized monoclonal antibody, targets the CC chemokine receptor 4. In nephrology, Kyowa Kirin's offerings feature CONIEL, a calcium channel blocker for hypertension and angina pectoris, along with erythropoiesis stimulating agents like ESPO and NESP. Treatments for secondary hyperparathyroidism include REGPARA and the oral calcimimetics agent ORKEDIA. Crysvita, a recombinant human monoclonal IgG1 antibody, is specifically designed to target fibroblast growth factor 23. For central nervous system disorders, Nouriast/Nourianz acts as an adenosine receptor antagonist in Parkinson's disease. Immunological conditions and allergies are addressed by ALLELOCK, an antihistamine, and LUMICEF, a biological therapy for moderate to severe plaque psoriasis. Additional products include Moventig, a mu-opioid receptor antagonist for opioid-induced constipation, and Romiplate/Nplate, a genetically recombinant protein that stimulates platelet production via thrombopoietin receptors. Beyond its existing portfolio, Kyowa Kirin is actively expanding its pipeline through strategic collaborations. A notable partnership with Amgen Inc. involves the co-development and future commercialization of KHK4083. This Phase 3-ready asset is an anti-OX40 fully human monoclonal antibody intended for the treatment of atopic dermatitis. Tracing its origins back to its incorporation in 1949, the company adopted its current name, Kyowa Kirin Co., Ltd., in June 2019, previously operating as Kyowa Hakko Kirin Co., Ltd. It maintains its headquarters in Tokyo, Japan, and operates as a subsidiary of Kirin Holdings Company, Limited.
Compare KYKOF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full KYKOF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open KYKOF position with:
🌍 KYKOF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold KYKOF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.91% | 0.11% | $291 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.47% | -0.33% | $247 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.33% | -0.47% | $233 / yr |
| 🇬🇧 UK ISA | 0% | 2.91% | 0.11% | $291 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.66% | -0.14% | $266 / yr |
| 🇨🇦 TFSA | 0% | 2.91% | 0.11% | $291 / yr |
| 🇨🇦 CA Taxable | 25% | 2.18% | -0.62% | $218 / yr |
| 🇦🇺 Super (pension) | 15% | 2.47% | -0.33% | $247 / yr |
| 🇦🇺 AU Taxable | 30% | 2.04% | -0.76% | $204 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.14% | -0.66% | $214 / yr |
| 🇫🇷 FR Taxable | 30% | 2.04% | -0.76% | $204 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 KYKOF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.42/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 KYKOF Dividend Payment Schedule
KYKOF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 KYKOF vs Healthcare Benchmarks
How KYKOF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for KYKOF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ KYKOF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the KYKOF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Kyowa Kirin Co., Ltd. (KYKOF) is currently trading at $14.43, 59% below its 52-week high. The current dividend yield is 2.91% based on an annual payout of $0.42 per share.
KYKOF (Kyowa Kirin Co., Ltd.) — 2.91% Dividend Yield Analysis
Kyowa Kirin Co., Ltd. (KYKOF) is a healthcare stock currently trading at $14.43 with a dividend yield of 2.91%. The company pays an annual dividend of $0.42 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, KYKOF has grown its dividend at a compound annual rate of 34.2%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.